Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An evaluation of artificial intelligence assisted prostate biopsy reporting in the Articulate Pro study.

NPJ digital medicine·2026
Same author

Use of UK national health databases for detecting intra-cranial aneurysm rupture in the Risk of Aneurysm Rupture (ROAR) study.

PLOS digital health·2026
Same author

Full BLOOD count TRends for colorectal cAnCer deteCtion (BLOODTRACC): external validation of dynamic clinical prediction models for early detection of colorectal cancer in primary care.

BMC cancer·2026
Same author

Estimating Rupture Risk of Intracranial Aneurysms: What We Know, What We Do Not Know, and What We Need.

Stroke·2026
Same author

A UK national prospective cohort study investigating current practices in single-event multilevel surgery for children with bilateral cerebral palsy and its impact on gait and function: the CPinBOSS study.

The bone & joint journal·2025
Same author

Exploring patient and clinician opinions, perspectives and acceptance of the use of artificial intelligence in the histological diagnosis of prostate cancer.

BJUI compass·2025
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Related Experiment Video

Updated: Jun 24, 2026

Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

Rivastigmine for Alzheimer's disease.

Jacqueline Birks1, John Grimley Evans, Vasso Iakovidou

  • 1Centre for Statistics in Medicine, University of Oxford, Wolfson College, Linton Road, Oxford, UK, OX2 6UD. jacqueline.birks@csm.ox.ac.uk

The Cochrane Database of Systematic Reviews
|April 17, 2009
PubMed
Summary
This summary is machine-generated.

Rivastigmine (exelon) offers significant benefits for Alzheimer's disease patients, improving cognitive function and daily living activities. High doses showed greater efficacy but increased side effects, while a lower-dose transdermal patch offered a better safety profile.

Related Experiment Videos

Last Updated: Jun 24, 2026

Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Alzheimer's disease (AD) is a leading cause of dementia in older adults.
  • Cholinesterase inhibitors enhance cholinergic neurotransmission to manage AD symptoms.
  • Rivastigmine offers improved specificity and a lower risk of adverse effects compared to earlier treatments like tacrine.

Purpose of the Study:

  • To evaluate the clinical effectiveness and safety of rivastigmine in patients diagnosed with dementia of the Alzheimer's type.

Main Methods:

  • Systematic review of unconfounded, double-blind, randomized trials comparing rivastigmine to placebo in Alzheimer's disease patients.
  • Searches conducted across major databases including Cochrane Library, MEDLINE, EMBASE, PsycINFO, CINAHL, and LILACS.
  • Data extraction and quality assessment performed by a single reviewer.

Main Results:

  • Nine trials involving 4775 participants demonstrated that high-dose rivastigmine (6-12 mg/day) significantly improved cognitive function (ADAS-Cog) and activities of daily living (PDS) compared to placebo.
  • Lower doses showed benefits in cognitive function but not statistically significant for daily living.
  • High-dose rivastigmine was associated with increased gastrointestinal and neurological side effects; however, a lower-dose transdermal patch showed comparable efficacy with fewer adverse events.

Conclusions:

  • Rivastigmine is beneficial for mild to moderate Alzheimer's disease, improving cognitive function, daily living, and dementia severity.
  • Adverse events are consistent with rivastigmine's cholinergic mechanism.
  • A lower-dose transdermal rivastigmine patch demonstrates comparable efficacy to capsules and higher-dose patches, with a significantly improved safety profile regarding side effects.